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This prospective observational study explored the efficacy and tolerability of levetiracetam (LEV) in a prospective series of 200
patients with refractory epilepsy attending a single epilepsy service. Patients were started on adjunctive LEV using one of two
titration schedules (slow and fast) and patients were studied for at least 6 months after commencing LEV. Fifty-three patients
had severe learning disabilities. 14.3% became seizure free, 57.7% showed >50% reduction, 15.4% showed seizure increase.
Patients with learning disability showed less positive but still very worthwhile results. A highly significant improvement in
clinical outcomes overall is shown (P < 0.0001). 56.6% showed no adverse effects, 27.4% showed minor adverse effects, 16%
were withdrawn. The most common adverse effect causing drug withdrawal was seizure exacerbation (12%) which was much
commoner in primary generalised epilepsies (P = 0.00035). LEV appears to be an effective and well-tolerated anti-epileptic
drug in drug resistant partial epilepsies.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
The new anti-epileptic drug levetiracetam (LEV) has
an unknown mechanism of action but has demon-
strated novel anti-epileptic activity in various animal
models1, 2. The effectiveness of this drug as adjunc-
tive anti-epileptic therapy has been established in
three multicentre, well-controlled phase III studies in
patients with a history of partial-onset seizures, with
or without secondary generalisation3–5. The pooled
data has been reviewed and has demonstrated con-
sistent anti-seizure activity in this group of patients6.
Safety data from these trials had been reviewed by
Harden7. Long-term continuation of LEV has been
demonstrated in a continuation study8, suggesting
a retention rate of 60% after 1 year and 32% af-
ter 5 years. In that review 13% of patients became
seizure-free for at least 6 months.
LEV has therefore been shown to have proven ef-
ficacy as add-on therapy in partial-onset seizures and
there is some evidence for its efficacy in primary
generalised seizures9, 10.
Whilst randomised placebo-controlled, fixed-dose
clinical trials are essential to establish the efficacy
and tolerability of a new AED, such studies may be
of relatively limited relevance in the practical use of
a new drug in everyday clinical practice. The cur-
rent prospective observational study, carried out in a
specialist epilepsy centre, aims to demonstrate and
explore the use of LEV in a population of patients
with refractory epilepsy, many of whom also had
significant learning disabilities.
METHOD
Prospective data were analysed in a consecutive series
of all patients started on LEV at the Burden Centre for
Neuropsychiatry, Neuropsychology and Epileptology
during the first year after the drug was licensed. This
population of patients all had refractory epilepsy and
had all been treated previously with multiple AEDs
(mean of 2.3 for primary generalised and 4.6 for lo-
calisation related epilepsies). All patients remained
on alternative AEDs at the start of the study and all
patients had continued to have seizures for more than
2 years in spite of treatment with a range of AEDs.
One hundred and seventy-five patients were studied
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prospectively, all of whom were studied for 6 or more
months after starting LEV therapy. The age range of
patients was from 15 to 73 years (median 42 years)
and the length of history of epilepsy was recorded
as being between 2 and 51 years (median 12 years).
Data were obtained on 200 patients but efficacy data
have not been analysed on 25 patients who were on
LEV for less than 6 months at the time of analysis. Of
the 175 patients studied, 92 were male and 83 were
female. Twenty-two patients (12.6%) had primary
generalised epilepsy whilst 153 (87.4%) had partial
seizures with or without generalisation.
Patients were asked to document their seizures for at
least 3 months before starting on LEV and maintained
on an unchanged dosage of previous AEDs for that
period. Patients were taking a mean of 2.2 other AEDs
at the onset of LEV treatment.
LEV dosage was titrated at two different rates.
Build-up to 3000 mg daily over a period of 6 weeks
was regarded as ‘fast rate’ and build-up to 2000 mg
daily over 8 weeks was regarded as a ‘slow rate’.
Initially ‘fast rate’ was used, then it was decided to
change to ‘slow rate’ after the first 6 months of the
study. Sixty-four patients (37%) underwent fast rate
titration whilst 111 patients (63%) underwent slow
rate titration. If the patient was seizure-free on either
the 2000 mg/day dose or the 3000 mg/day dose, then
no alteration in the regime was made unless further
seizures occurred. Wherever possible, concomitant
AEDs were withdrawn. Patients were seen every 8–12
weeks by one or other of three senior clinicians.
At each visit the patient’s seizure chart was checked
and any adverse effects were documented. Discontin-
uation of LEV was undertaken if there was the devel-
opment of unacceptable side effects, exacerbation of
epilepsy or lack of efficacy.
Fifty-three (30.3%) of the overall population of
patients had severe or profound learning disabilities.
RESULTS
Efficacy
Overall, 25 (14.3%) of the 175 patients became
seizure-free for at least 6 months. A further 101 pa-
tients (57.7%) showed a greater than 50% reduction in
seizure frequency for at least a 6-month period whilst
28 patients (16%) showed no significant change and
21 (15.4%) showed a significant increase in seizure
frequency. During the study period (6–20 months), the
longest period of seizure freedom was 19 months and
15 patients attained seizure freedom for more than
12 months. These results show a highly significant
improvement when comparing pre LEV treatment
condition with condition on LEV (P < 0.0001).
The length of history of epilepsy was assessed and
was not related to the likelihood of seizure freedom
with LEV.
No significant relationship was found between
seizure freedom with LEV and any particular addi-
tional AED taken, but sample sizes are small for each
individual drug. Similarly, no particular combination
of AEDs with LEV was found to result in a significant
increase in adverse effects.
The relationship between seizure freedom and either
primary generalised- or localisation-related seizures
was assessed, four patients (18%) with primary gen-
eralised seizures became completely seizure-free for
more than 6 months whilst 21 patients (13.7%) with
localisation-related epilepsy became seizure free for
more than 6 months. This is not a significant differ-
ence. It must be born in mind that this was a partic-
ularly treatment resistant group, many with multiple
problems in addition to epilepsy.
Of the 53 patients with severe or profound learning
disabilities, 7.6% showed complete seizure freedom
whilst 69.8% showed a greater than 50% seizure re-
duction. This compared with the population without
learning disability, of whom 17.2% showed com-
plete seizure freedom whilst 52.6% showed greater
than 50% seizure reduction. Figures for increased
seizure frequency were about the same (learning
disabled population—11.3%, non learning disabled
population—12.3%).
At the end of the study period, 12 patients (6.8%)
were settled on mono therapy with LEV, three showing
complete seizure cessation, five showing more than
90% reduction in seizure frequency and four showing
greater than 50% reduction in seizure frequency, two
of whom commented that their seizures were much
less intense.
Adverse effects
Adverse effects were assessed according to a 3-point
scale, 0 meaning no adverse effects experienced, −1
referring to minor adverse effects but continuing with
treatment and−2 referring to adverse effects resulting
in treatment withdrawal.
Ninety-nine patients (56.6%) experienced no ad-
verse effects, 48 (27.4%) experienced minor adverse
effects but continued with treatment and 28 patients
(16%) were withdrawn either because of adverse ef-
fects or, more commonly, due to lack of efficacy or ex-
acerbation of seizure frequency. Twenty-one patients
(12%) were withdrawn primarily due to increase in
seizure frequency or a combination of this with other
adverse effects. Two patients showed the develop-
ment of psychosis, at a late stage after 6 months of
complete or near seizure freedom. The most common
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Table 1: Adverse effects reported on LEV.
Adverse effect Reported Lead to
discontinuation
Number Percent Number Percent
Sleepiness 31 17.7 4 2.3
Aggression 18 10.3 7 4.0
Dizziness 8 4.6 3 1.7
Headache 4 2.3 0 0
Confusion 3 1.7 1 0.6
Rash 2 1.1 0 0
Erectile dysfunction 1 0.6 1 0.6
Nausea 2 1.1 1 0.6
Diplopia 2 1.1 0 0
Hallucinations 1 0.6 1 0.6
Seizure exacerbation
(often with other
adverse effects)
21 12 21 12
adverse effect other than seizure exacerbation to result
in drug withdrawal was the development of aggres-
sion, all seven such patients were learning disabled and
in five of these there was associated seizure frequency
increase whilst in one there had been seizure cessation.
Adverse effects are noted in Table 1. Significantly
more patients with primary generalised seizures were
withdrawn due to adverse effects, including seizure
exacerbation. (45.45% primary generalised cf. 11.76%
partial, Fisher’s exact probability = 0.00035.)
Patients with ‘fast rate’ titration (0–3000 mg/day
within 6 weeks) were compared with ‘slow rate’ dose
titration (0–2000 mg/day over 8 weeks). Those who
completed these schedules did not show any difference
in overall efficacy or in frequency or severity of ad-
verse effects. Thus, on the one hand, slower build-up
of medication did not appear to reduce the likelihood
of the development of adverse effects, on the other
hand 2000 mg/day, in this study, seems as effective for
most patients as is 3000 mg/day. Six patients did so
well that they did not need to build up to 2000 mg/day,
two patients have remained seizure-free for more than
12 months on 500 mg/day and a further two patients
have remained seizure-free for more than 12 months
on 1000 mg/day. These patients were all in the ‘slow
rate’ titration group.
DISCUSSION
This study has demonstrated continued efficacy of
LEV in a population of patients with refractory
epilepsy who are being treated in an epilepsy clinic
rather than in a research setting. The expected dif-
ferences in efficacy of LEV in populations with and
without learning disability has been demonstrated,
patients without learning disability have shown a
17.2% seizure freedom rate for more than 6 months
whilst those with learning disability have shown a
7.6% seizure freedom rate. Nevertheless, even in the
population with learning disabilities, almost 70%
have shown a greater than 50% reduction in seizure
frequency. Adverse effect profiles have demonstrated
greater likelihood of adverse effects in those with
primary generalised seizures but not particularly in
those with learning disabilities. However, aggression
was seen more commonly as an adverse effect in the
learning disabled group. Whilst there have been sig-
nificant numbers of patients with primary generalised
epilepsy who have responded well to LEV, there has
been a significantly greater number who have shown
seizure exacerbation than in the population with
localisation-related epilepsy.
Smith et al.10 have reported marked efficacy in Ju-
venile Myoclonic Epilepsy, however, in our group two
of six patients with this condition showed early and
very marked exacerbation of myoclonus, one showing
his first tonic–clonic seizure for 5 years (without any
concomitant drug reduction). All the others did well
and were being seizure-free for 6 or more months.
In 85 patients (48.6%) concomitant AEDs were
withdrawn, with 12 patients being on LEV monother-
apy at the close of the study. In the majority of
cases LEV replaced another AED, whilst in 28 pa-
tients more than one AED was withdrawn during the
20-month study period.
CONCLUSION
LEV has been shown, in this population of 200 pa-
tients with refractory epilepsy, to be an effective,
safe and important addition to the anti-epileptic ar-
mamentarium. All patients in this study had been
previously treated with a wide range of AEDs, with-
out success—hence to achieve 14.3% seizure free-
dom (17.2% in the non learning disabled group) is
remarkable. To do so with only 16% withdrawal due
to adverse effects makes the drug still more useful in
clinical practice. As with other AEDs seizure relief
can, rarely, be associated with the development of
psychosis. Exacerbation of seizures appears to be the
most common serious adverse effect, especially in
the primary generalised group—but this group may
also do very well in some cases. In the learning dis-
abled group aggressive behaviour change is relatively
common.
LEV appears, in clinical practice, to be an important
new AED with a broad spectrum of activity.
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